Rudy Giuliani’s Consulting Firm Had Hand In Halting Florida’s Opioid Investigation
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
Purdue Pharma’s Sales Pitch Downplayed Risks Of Opioid Addiction
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.
How Rival Opioid Makers Sought To Cash In On Alarm Over OxyContin’s Dangers
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
Tennessee-Based Pain Management Group To Close Clinics Amid Financial Turmoil
The CEO of Comprehensive Pain Specialists was indicted in April. Now the group is closing clinics across several states.
How America Got Hooked On A Deadly Drug
An inside look at how Purdue Pharma pushed OxyContin despite risks of addiction and fatalities.
Estudiante universitaria recibe una cuenta de $17,850 por una prueba de orina
Esta historia forma parte de una serie en la que KHN investigará cuentas médicas sorprendentes enviadas por los usuarios.
‘Bill Of The Month’: A College Student’s $17,850 Drug Test
Kaiser Health News, in collaboration with NPR, kicks off a series that will examine and decode your perplexing medical bills.
Pain Hits After Surgery When A Doctor’s Daughter Is Stunned By $17,850 Urine Test
Elizabeth Moreno got hit with a $17,850 bill from a Texas lab after leaving a urine sample at her doctor’s office.
Doctors Make Big Money Testing Urine For Drugs, Then Ignore Abnormal Results
Medicare and insurers struggle to oversee a booming business in testing urine samples. In some cases, pain doctors’ lack of follow-through can turn fatal.
Liquid Gold: Pain Doctors Soak Up Profits By Screening Urine For Drugs
With the nation’s opioid crisis, urine testing has become a booming business and is especially lucrative for doctors who operate their own labs, a Kaiser Health News investigation finds. And dozens of practitioners have earned ‘the lion’s share’ of their Medicare income exclusively from urine drug screens.